Search company, investor...

The DNA Repair Company


Other Investors | Alive

About The DNA Repair Company

The DNA Repair Company was founded to bring recent scientific discoveries from the Dana Farber Cancer Institute and the Massachusetts Institute of Technology to the clinic to benefit cancer patients. Breakthroughs in understanding DNA repair mechanisms have led to new personalized approaches to cancer treatment, beginning with diagnostic tools that improve the efficacy of currently available cancer therapies, as well as drugs under development. DNAR exists to make these tools available to physicians with the goal of improving clinical outcomes.

Headquarters Location

Boston, Massachusetts, 02108,

United States

Missing: The DNA Repair Company's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: The DNA Repair Company's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing The DNA Repair Company

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

The DNA Repair Company is included in 1 Expert Collection, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

The DNA Repair Company Patents

The DNA Repair Company has filed 2 patents.

The 3 most popular patent topics include:

  • Amines
  • Analgesics
  • Cancer treatments
patents chart

Application Date

Grant Date


Related Topics




DNA, Molecular biology, DNA repair, Senescence, Molecular genetics


Application Date


Grant Date



Related Topics

DNA, Molecular biology, DNA repair, Senescence, Molecular genetics



The DNA Repair Company Frequently Asked Questions (FAQ)

  • Where is The DNA Repair Company's headquarters?

    The DNA Repair Company's headquarters is located at Boston.

  • What is The DNA Repair Company's latest funding round?

    The DNA Repair Company's latest funding round is Other Investors.

  • Who are the investors of The DNA Repair Company?

    Investors of The DNA Repair Company include Boston University Technology Development and Mohr Davidow Ventures.

  • Who are The DNA Repair Company's competitors?

    Competitors of The DNA Repair Company include Concert Pharmaceuticals, Regentis Biomaterials, Syndax Pharmaceuticals, SpiroGen, EpiCept, OptiMedica, Angstrom Pharmaceuticals, Pearl Therapeutics, Nanomed Pharmaceuticals, Link Medicine and 13 more.

Compare The DNA Repair Company to Competitors

Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..

Advanced Tissue Therapies

Bioceramic Therapeutics Limited is developing new kinds of material that help the body heal itself. The aim is to assist patients, especially the elderly, for whom normal tissue repair mechanisms do not result in possible medical outcomes. Such patients may have fractures or osteoporosis, need orthopedic or periodontal implants or have a condition that has damaged their bones.

Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

Link Medicine

Link Medicine is advancing disease-modifying technologies targeted at Alzheimer's, Parkinson's and other neurodegenerative diseases.

Oculus Innovative Sciences

Oculus Innovative Sciences develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform features a biocompatible, shelf-stable solution containing active oxychlorine compounds that is currently commercialized in the United States, Europe, India, China and Mexico for the treatment of infected wounds. The solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. The company's headquarters are in Petaluma, California, with operations in Europe and Latin America.

Cobrek Pharmaceuticals

Cobrek Pharmaceuticals is engaged in the research, development and commercialization of prescription drug therapies, delivery systems and applications that improve quality of life and enhance the lifestyle of patients across the adolescent and adult age-spectrum with particular attention to the needs of the aging population.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.